



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTO/SB/17 (05-03)

Approved for use through 04/30/2003. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

FEE TRANSMITTAL for FY 2003

Effective 01/01/2003. Patent fees are subject to annual revision.

Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT

(\$)

Complete if Known	
Application Number	09/903,376
Filing Date	July 10, 2001
First Named Inventor	Thomas J. Brennan
Examiner Name	Quang Nguyen
Art Unit	1636
Attorney Docket No.	R-599

RECEIVED
JUN 02 2003
TECH CENTER 1600/2000

METHOD OF PAYMENT (check all that apply)				FEE CALCULATION (continued)																																																																			
<input type="checkbox"/> Check <input type="checkbox"/> Credit card <input type="checkbox"/> Money Order <input type="checkbox"/> Other <input type="checkbox"/> None <input checked="" type="checkbox"/> Deposit Account: Deposit Account Number: 50-1271 Deposit Account Name: Deltagen, Inc.				3. ADDITIONAL FEES <table border="1"> <thead> <tr> <th>Large Entity</th> <th>Small Entity</th> </tr> </thead> <tbody> <tr> <td>Fee Code (\$)</td> <td>Fee Code (\$)</td> </tr> <tr> <td>1051</td> <td>2051</td> </tr> <tr> <td>1052</td> <td>2052</td> </tr> <tr> <td>1053</td> <td>1053</td> </tr> <tr> <td>1812</td> <td>1812</td> </tr> <tr> <td>1804</td> <td>1804</td> </tr> <tr> <td>1805</td> <td>1805</td> </tr> <tr> <td>1251</td> <td>2251</td> </tr> <tr> <td>1252</td> <td>2252</td> </tr> <tr> <td>1253</td> <td>2253</td> </tr> <tr> <td>1254</td> <td>2254</td> </tr> <tr> <td>1255</td> <td>2255</td> </tr> <tr> <td>1401</td> <td>2401</td> </tr> <tr> <td>1402</td> <td>2402</td> </tr> <tr> <td>1403</td> <td>2403</td> </tr> <tr> <td>1451</td> <td>1451</td> </tr> <tr> <td>1452</td> <td>2452</td> </tr> <tr> <td>1453</td> <td>2453</td> </tr> <tr> <td>1501</td> <td>2501</td> </tr> <tr> <td>1502</td> <td>2502</td> </tr> <tr> <td>1503</td> <td>2503</td> </tr> <tr> <td>1460</td> <td>1460</td> </tr> <tr> <td>1807</td> <td>1807</td> </tr> <tr> <td>1806</td> <td>1806</td> </tr> <tr> <td>8021</td> <td>8021</td> </tr> <tr> <td>1809</td> <td>2809</td> </tr> <tr> <td>1810</td> <td>2810</td> </tr> <tr> <td>1801</td> <td>2801</td> </tr> <tr> <td>1802</td> <td>1802</td> </tr> <tr> <td colspan="2">Fee Description</td> </tr> <tr> <td colspan="2">Fee Paid</td> </tr> </tbody> </table>				Large Entity	Small Entity	Fee Code (\$)	Fee Code (\$)	1051	2051	1052	2052	1053	1053	1812	1812	1804	1804	1805	1805	1251	2251	1252	2252	1253	2253	1254	2254	1255	2255	1401	2401	1402	2402	1403	2403	1451	1451	1452	2452	1453	2453	1501	2501	1502	2502	1503	2503	1460	1460	1807	1807	1806	1806	8021	8021	1809	2809	1810	2810	1801	2801	1802	1802	Fee Description		Fee Paid	
Large Entity	Small Entity																																																																						
Fee Code (\$)	Fee Code (\$)																																																																						
1051	2051																																																																						
1052	2052																																																																						
1053	1053																																																																						
1812	1812																																																																						
1804	1804																																																																						
1805	1805																																																																						
1251	2251																																																																						
1252	2252																																																																						
1253	2253																																																																						
1254	2254																																																																						
1255	2255																																																																						
1401	2401																																																																						
1402	2402																																																																						
1403	2403																																																																						
1451	1451																																																																						
1452	2452																																																																						
1453	2453																																																																						
1501	2501																																																																						
1502	2502																																																																						
1503	2503																																																																						
1460	1460																																																																						
1807	1807																																																																						
1806	1806																																																																						
8021	8021																																																																						
1809	2809																																																																						
1810	2810																																																																						
1801	2801																																																																						
1802	1802																																																																						
Fee Description																																																																							
Fee Paid																																																																							
The Director is authorized to: (check all that apply) <input type="checkbox"/> Charge fee(s) indicated below <input type="checkbox"/> Credit any overpayments <input type="checkbox"/> Charge any additional fee(s) during the pendency of this application <input type="checkbox"/> Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.																																																																							
FEE CALCULATION																																																																							
1. BASIC FILING FEE																																																																							
Large Entity		Small Entity		<table border="1"> <thead> <tr> <th>Fee Code (\$)</th> <th>Fee Code (\$)</th> <th>Fee Description</th> <th>Fee Paid</th> </tr> </thead> <tbody> <tr> <td>1001</td> <td>750</td> <td>2001</td> <td>375</td> <td>Utility filing fee</td> <td></td> </tr> <tr> <td>1002</td> <td>330</td> <td>2002</td> <td>165</td> <td>Design filing fee</td> <td></td> </tr> <tr> <td>1003</td> <td>520</td> <td>2003</td> <td>260</td> <td>Plant filing fee</td> <td></td> </tr> <tr> <td>1004</td> <td>750</td> <td>2004</td> <td>375</td> <td>Reissue filing fee</td> <td></td> </tr> <tr> <td>1005</td> <td>160</td> <td>2005</td> <td>80</td> <td>Provisional filing fee</td> <td></td> </tr> <tr> <td colspan="2">SUBTOTAL (1)</td> <td colspan="2">(\$)</td> <td></td> <td></td> <td></td> <td></td> </tr> </tbody> </table>				Fee Code (\$)	Fee Code (\$)	Fee Description	Fee Paid	1001	750	2001	375	Utility filing fee		1002	330	2002	165	Design filing fee		1003	520	2003	260	Plant filing fee		1004	750	2004	375	Reissue filing fee		1005	160	2005	80	Provisional filing fee		SUBTOTAL (1)		(\$)																											
Fee Code (\$)	Fee Code (\$)	Fee Description	Fee Paid																																																																				
1001	750	2001	375	Utility filing fee																																																																			
1002	330	2002	165	Design filing fee																																																																			
1003	520	2003	260	Plant filing fee																																																																			
1004	750	2004	375	Reissue filing fee																																																																			
1005	160	2005	80	Provisional filing fee																																																																			
SUBTOTAL (1)		(\$)																																																																					
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE																																																																							
Total Claims		Extra Claims		Fee from below		Fee Paid																																																																	
Independent Claims																																																																							
Multiple Dependent																																																																							
Large Entity		Small Entity		<table border="1"> <thead> <tr> <th>Fee Code (\$)</th> <th>Fee Code (\$)</th> <th>Fee Description</th> <th>Fee Paid</th> </tr> </thead> <tbody> <tr> <td>1202</td> <td>18</td> <td>2202</td> <td>9</td> <td>Claims in excess of 20</td> <td></td> </tr> <tr> <td>1201</td> <td>84</td> <td>2201</td> <td>42</td> <td>Independent claims in excess of 3</td> <td></td> </tr> <tr> <td>1203</td> <td>280</td> <td>2203</td> <td>140</td> <td>Multiple dependent claim, if not paid</td> <td></td> </tr> <tr> <td>1204</td> <td>84</td> <td>2204</td> <td>42</td> <td>** Reissue independent claims over original patent</td> <td></td> </tr> <tr> <td>1205</td> <td>18</td> <td>2205</td> <td>9</td> <td>** Reissue claims in excess of 20 and over original patent</td> <td></td> </tr> <tr> <td colspan="2">SUBTOTAL (2)</td> <td colspan="2">(\$)</td> <td></td> <td></td> <td></td> <td></td> </tr> </tbody> </table>				Fee Code (\$)	Fee Code (\$)	Fee Description	Fee Paid	1202	18	2202	9	Claims in excess of 20		1201	84	2201	42	Independent claims in excess of 3		1203	280	2203	140	Multiple dependent claim, if not paid		1204	84	2204	42	** Reissue independent claims over original patent		1205	18	2205	9	** Reissue claims in excess of 20 and over original patent		SUBTOTAL (2)		(\$)																											
Fee Code (\$)	Fee Code (\$)	Fee Description	Fee Paid																																																																				
1202	18	2202	9	Claims in excess of 20																																																																			
1201	84	2201	42	Independent claims in excess of 3																																																																			
1203	280	2203	140	Multiple dependent claim, if not paid																																																																			
1204	84	2204	42	** Reissue independent claims over original patent																																																																			
1205	18	2205	9	** Reissue claims in excess of 20 and over original patent																																																																			
SUBTOTAL (2)		(\$)																																																																					
** or number previously paid, if greater; For Reissues, see above Other fee (specify) _____																																																																							
*Reduced by Basic Filing Fee Paid SUBTOTAL (3) (\$)																																																																							
985.00																																																																							

SUBMITTED BY				
Name (Print/Type)	Nicole A. Verona	Registration No. (Attorney/Agent)	47,153	Telephone 650-569-5100
Signature	Nicole A. Verona		Date	May 22, 2003

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



1636
S

PTO/SB/21 (03-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

4

Application Number

09/903,376

Filing Date

July 10, 2001

First Named Inventor

Thomas J. Brennan

Art Unit

1636

Examiner Name

Quang Nguyen

RECEIVED

JUN 02 2003
TECH CENTER 1600/2900

ENCLOSURES (Check all that apply)

<input checked="" type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input checked="" type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Remarks	<input type="checkbox"/> After Allowance Communication to a Technology Center (TC) <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Other Enclosure(s) (please identify below):
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual	Nicole A. Verona, Reg. No. 47,153
Signature	<i>Nicole A. Verona</i>
Date	May 22, 2003

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date:

May 22, 2003

Typed or printed	Don Mixon
Signature	<i>Don Mixon</i>
	Date May 22, 2003

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



O I P E
UNITED STATES PATENT AND TRADEMARK OFFICE
MAY 28 2003
C48

PATENT & TRADEMARK OFFICE

FILING DATE
07/10/2001

FIRST NAMED INVENTOR

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/903,376	07/10/2001	Thomas J. Brennan	R-599	8327

7590 11/22/2002

DELTAGEN, INC.
1003 Hamilton Avenue
Menlo Park, CA 94025

EXAMINER

PARAS JR, PETER

ART UNIT	PAPER NUMBER
----------	--------------

1632

DATE MAILED: 11/22/2002

Please find below and/or attached an Office communication concerning this application or proceeding.

RECEIVED

JUN 02 2003

TECH CENTER 1600/2900

RECEIVED 2-27-03
RECEIVED
NOV 26 2002
BY:



Office Action Summary

	Application No.	Applicant(s)
	09/903,376	BRENNAN, THOMAS J.
Examiner	Art Unit	
Peter Paras, Jr.	1632	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on _____.
- 2a) This action is FINAL. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 1-27 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) Claim(s) _____ is/are allowed.
- 6) Claim(s) _____ is/are rejected.
- 7) Claim(s) _____ is/are objected to.
- 8) Claim(s) 1-27 are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) The proposed drawing correction filed on _____ is: a) approved b) disapproved by the Examiner.
If approved, corrected drawings are required in reply to this Office action.
- 12) The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

- 13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) All b) Some * c) None of:
 - 1. Certified copies of the priority documents have been received.
 - 2. Certified copies of the priority documents have been received in Application No. _____.
 - 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.
- 14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
 - a) The translation of the foreign language provisional application has been received.
- 15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

1) <input type="checkbox"/> Notice of References Cited (PTO-892)	4) <input type="checkbox"/> Interview Summary (PTO-413) Paper No(s). _____.
2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)	5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)
3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____.	6) <input type="checkbox"/> Other: _____

RECEIVED
JUN 02 2003
TECH CENTER 1600/2900

DETAILED ACTION

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-4, drawn to a targeting construct comprising nucleotide sequences homologous to a 5-HT-2B gene and a method of producing a targeting construct, classified in class 435, subclass 320.1.
- II. Claims 5-7, 9, and 24 drawn to cells comprising a disruption in a 5-HT-2B gene, classified in class 435, subclass 325.
- III. Claims 8, 10, and 17-23, drawn to a transgenic non-human animal, particularly a mouse, comprising a disruption in a 5-HT-2B gene, and a method of making the same, classified in classes 800, 800, and 800 subclass 13, 18, and 25.
- IV. Claims 11-12, drawn to methods of identifying agents that modulate the expression of a 5-HT-2B gene or modulate the function of a 5-HT-2B comprising screening said agents in a transgenic non-human animal, classified in class 800, subclass 3.
- V. Claims 13-15, drawn to methods of identifying agents that modulate expression of a 5-HT-2B gene or function of a 5-HT-2B in a cell *in vitro*, classified in class 435, subclass 7.2.
- VI. Claim 16, drawn to an unknown agent is unclassifiable.

- VII. Claim 27, drawn to phenotypic data, in an electronic database, associated with a transgenic mouse, classified in class 702, subclass 19.
- VIII. Claim 25, drawn to methods of identifying an agent that modulates a phenotype associated with or behavior associated with a disruption in a 5-HT-2B gene, comprising screening agents in a transgenic mouse, classified in class 800, subclass 3.
- IX. Claim 26, drawn to an agonist or antagonist of a 5-HT-2B receptor is unclassifiable as the agonist or antagonist is unknown.

The products of Inventions I, II, III, VI, VII, and IX each from the other are distinct each from the other. Inventions are distinct if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions have different modes of operation, different function, and different effects. The products of Groups I, II, III, VI, VII, and IX have different chemical structures, are made by different methods, and can be used in different methods which require different technical considerations and materially different reagents. For example, the transgenic animal non-human animal of Group III can be used as a model of disease while the targeting construct of Group I may be used to disrupt a gene in a somatic cell *in vitro*, the cells of Group II may be used to isolate a protein, and the data of Group VII may be used for statistical analysis in a database. Also, the agent of group VI has a different chemical structure from the targeting construct, cells, and transgenic

non-human animals of Groups I, II, and III respectively, and may be used in different methods, which require different technical considerations with respect to modulation of a 5-HT-2B. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, different classifications, and separate search requirement, restriction for examination purposes as indicated is proper.

Although there are no provisions under the section for "Relationship of Inventions" in MPEP 806.05 for inventive groups that are directed to different methods, restriction is deemed to be proper between groups IV, V, and VIII because their methods appear to constitute patentably distinct inventions, each with a distinct purpose and further comprising distinct methodologies and using different products. For example, the method of Group IV requires the use of a transgenic non-human animal while the method of Group V requires the use of a cell *in vitro*. Because these inventions are distinct for the reasons given above and a separate search is required for each of Groups IV, V and VIII, restriction for examination purposes as indicated is proper.

The products of Inventions I, II, III, VI, VII, and IX and the methods of Invention IV, V, VIII are distinct. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions have different modes of operation, different function, and different effects each from the other. The products of Groups I, II, III, VI, VII, and IX can

be used in methods that require different technical considerations and materially different reagents from the methods of Groups IV, V, VIII. The method of Group IV can be practiced with products that have different chemical structures than the products of Groups I, II, III, VI, VII, and IX. For example, the transgenic animals of Group III may be used to produce antibodies while the method of Group IV may be used to identify agents that modulate the expression of a 5-HT-2B. Further, the method of Group IV may be practiced with agents that have different chemical structures from the agent of Group VI. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, different classifications, and separate search requirement, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Any inquiry concerning this communication or earlier communications from the examiner(s) should be directed to Peter Paras, Jr., whose telephone number is 703-308-8340. The examiner can normally be reached Monday-Friday from 8:30 to 4:30 (Eastern time).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Deborah Reynolds, can be reached at 703-305-4051. Papers related to this application may be submitted by facsimile transmission. Papers should be faxed via the PTO Fax Center located in Crystal Mall 1. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). The CM1 Fax Center numbers are (703) 308-4242 and (703) 305-3014.

Inquiries of a general nature or relating to the status of the application should be directed to Dianiece Jacobs whose telephone number is (703) 305-3388.

Peter Paras, Jr.
Art Unit 1632

Pete Paras
Art Unit 1632